Table 1 Preoperative baseline data of study group and control group
|  | Group A ASA alone %(n = 106) | Group B Ticagrelor +ASA %(n = 55) | p-Value |
|---|---|---|---|
Age (years) | 64 ± 8 | 61 ± 10 | 0.034 |
Sex, Male (n,%) | 87Â (92) | 96Â (53) | 0.092 |
Risk profile | |||
 Diabetes Mellitus | 42 (45) | 47 (26) | 0.622 |
 Hypertension | 71 (75) | 76 (42) | 0.461 |
 Hyperlipidemia | 75 (80) | 76 (42) | 0.850 |
 Smoking, current | 38 (40) | 54 (30) | 0.002 |
 Smoking, past | 12 (13) | 5 (3) | 0.267 |
 Obesity | 16 (17) | 25 (15) | 0.207 |
Previous CAD | 36Â (38) | 40Â (22) | 0.733 |
 Coronary stents in situ | 26 (28) | 51 (25) | 0.003 |
 Paroxysmal atrial fibrillation | 7 (7) | 2 (1) | 0.054 |
 Renal Failure | 3 (3) | 5 (3) | 0.414 |
 Congestive heart failure | 18 (19) | 13 (7) | 0.500 |
 Peripheral vascular disease | 7 (7) | 2 (1) | 0.265 |
 Cerebrovascular accident | 6 (6) | 9 (5) | 0.514 |
 COPD | 6 (6) | 5 (2) | 0.716 |
Medications | |||
 Aspirin | 92 (97) | 98(54) | 0.137 |
 Anticoagulant therapy (VKA/DOACs) | 8 (9) | 2 (1) | 0.254 |
 ACEi/ARB | 48 (51) | 61 (38) | 0.002 |
 β Blockers | 72 (76) | 85 (47) | 0.085 |
 Calcium Channel Blockers | 26 (28) | 27 (15) | 0.854 |